Clinical Trials Directory

Trials / Completed

CompletedNCT06720454

Study on Single-cell Regulons Atlas of Pancreatic Ductal Adenocarcinoma

Multiplex Immunofluorescence Staining of Pathological Tissue Microarray

Status
Completed
Phase
Study type
Observational
Enrollment
68 (actual)
Sponsor
Tiejun Ying · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers

Summary

The first purpose of this study is to reveal the gene regulatory network of pancreatic cancer by analyzing single-cell transcriptome sequencing data and to draw a pancreatic cancer regulator map. In addition, bulk transcriptome sequencing data are combined to construct and verify the genetic prognostic model of pancreatic cancer regulators, providing clinical tools for accurate prognostic stratification and personalized treatment of pancreatic cancer patients. The second purpose of this study is to explore the molecular mechanism by which the key oncogene in the gene prognostic model promotes pancreatic cancer advance. New ideas and scientific basis are provided for finding potential molecular targets for the treatment of pancreatic cancer. Thus, the investigators included a Tissue Microarray (TMA)-based cohort of 68 PDAC patient tissue samples. TMA was obtained from OUTDO BIOTECH (Shanghai, China). The study was approved by the institutional review board, and ethics document number is YB M-05-01.

Conditions

Timeline

Start date
2019-01-02
Primary completion
2020-02-25
Completion
2024-04-21
First posted
2024-12-06
Last updated
2024-12-06

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06720454. Inclusion in this directory is not an endorsement.